In this pitch deck, analysts Gustav Strand and Emma Rosberg present a comprehensive analysis of CareCloud, a US-based provider of cloud-based healthcare IT solutions to small and mid-sized medical practices. Recent share price weakness reflects lingering stigma tied to the 2023 goodwill impairment, selling pressure from income-focused preferred holders converted into common equity, and minimal sell-side coverage. However, CareCloud has a proven acquisition playbook, buying unprofitable RCM peers at bargains and turning them highly profitable within 3-9 months by shifting operations to an offshore workforce. The capital structure was fully cleaned up in May 2026, and cash flow now accrues entirely to shareholders and funds the acquisition model. A take-private offer, rejected as recently as 2024, underlines the appeal as a buyout target. The thesis supports 71% upside to the target share price.
Investment Thesis
● Reinvigorated M&A strategy: A modelled acquisition between H2 2026 and H1 2027 follows a playbook executed over 20 times, in which unprofitable targets are acquired at 0.6-1.0x EV/Sales and integrated into the offshore cost base, expanding EBITDA margins to 25-30%.
● Increased cash flow to common: The redemption of the final preferred shares eliminates USD 3.5m in annual dividends, while NOL tax shields protect profits from federal tax, freeing up cash flow for shareholders and further M&A.
● Buyout optionality: Rapid consolidation in healthcare IT has already reached CareCloud, with a take-private offer at USD 5.00 per share rejected by the board as insufficient in 2024, more than double the current share price